BioSpace News Archive

Abivax (Euronext Paris: FR0012333284 - ABVX) (the “Company”), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces its 2022 annual financial results, as of December 31, 2022, and provides an update on the progress of its product pipeline.

MDxHealth SA, a commercial-stage precision diagnostics company, received notice that its Select mdx for Prostate Cancer test has successfully completed a rigorous technical assessment process with the Molecular Diagnostics Services Program developed by Palmetto GBA.

Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the second quarter of 2023, and financial outlook for full year 2023.

Alkermes plc will host a conference call and webcast presentation at 8:00 a.m. ET on Wednesday, April 26, 2023 to discuss the company’s first quarter financial results.

- Semler Scientific, Inc. announced that Eric Semler and William H.C. Chang, who collectively beneficially own more than 20% of Semler Scientific’s outstanding shares, will immediately join Semler Scientific’s board of directors as new independent directors.

Athersys, Inc. announced that it has closed its previously announced offering to sell 3,685,000 shares of the Company’s common stock in a registered direct offering and warrants to purchase 3,685,000 Shares at a purchase price per Share of $1.00 in a concurrent private placement.

GENFIT announced that it published in the April 19, 2023 French legal announcements bulletin n°47 its convening notice that the Combined Shareholders Meeting will be held on May 24, 2023, at 10:00am, at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.

Palatin Technologies today announced preliminary fiscal third quarter ended March 31, 2023 Vyleesi® product revenue results.

Surmodics, Inc. today announced that second quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, April 26.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced new preclinical data showing the positive effect of its novel pan-BET inhibitor, VYN201, in a preclinical model of idiopathic pulmonary fibrosis (“IPF”).